PL3411036T3 - 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie - Google Patents
3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanieInfo
- Publication number
- PL3411036T3 PL3411036T3 PL16888753T PL16888753T PL3411036T3 PL 3411036 T3 PL3411036 T3 PL 3411036T3 PL 16888753 T PL16888753 T PL 16888753T PL 16888753 T PL16888753 T PL 16888753T PL 3411036 T3 PL3411036 T3 PL 3411036T3
- Authority
- PL
- Poland
- Prior art keywords
- chk1
- preparations
- inhibitors
- applications
- checkpoint kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/073454 WO2017132928A1 (en) | 2016-02-04 | 2016-02-04 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| EP16888753.7A EP3411036B1 (en) | 2016-02-04 | 2016-02-04 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3411036T3 true PL3411036T3 (pl) | 2022-04-04 |
Family
ID=59500387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16888753T PL3411036T3 (pl) | 2016-02-04 | 2016-02-04 | 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11116767B2 (pl) |
| EP (1) | EP3411036B1 (pl) |
| JP (1) | JP6794609B2 (pl) |
| KR (1) | KR102159442B1 (pl) |
| CN (1) | CN108601781B (pl) |
| AU (1) | AU2016391377B2 (pl) |
| CA (1) | CA3013514C (pl) |
| DK (1) | DK3411036T3 (pl) |
| ES (1) | ES2906785T3 (pl) |
| HR (1) | HRP20220351T1 (pl) |
| HU (1) | HUE057976T2 (pl) |
| PL (1) | PL3411036T3 (pl) |
| PT (1) | PT3411036T (pl) |
| SI (1) | SI3411036T1 (pl) |
| TW (1) | TWI623533B (pl) |
| WO (1) | WO2017132928A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| ES3014705T3 (en) * | 2019-11-29 | 2025-04-24 | Novaonco Js Therapeutics Co Ltd | Diazaindole derivative and use thereof as chk1 inhibitor |
| TWI810426B (zh) * | 2020-01-10 | 2023-08-01 | 長庚大學 | 醫藥組合物於製備治療癌症藥物之用途與評估方法 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| EP4253377A4 (en) * | 2020-11-30 | 2024-10-16 | Sumitomo Pharma Co., Ltd. | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE |
| CN117715905A (zh) * | 2021-05-27 | 2024-03-15 | 无界生物公司 | 检查点激酶1（chk1）抑制剂及其用途 |
| GB202107924D0 (en) * | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| EP4455134A4 (en) | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IT202200000920A1 (it) | 2022-01-20 | 2023-07-20 | Fondazione St Italiano Tecnologia | "Derivati del 4-cromone come inibitori della polimerasi RdRp del virus SARS-CoV-2 e metodo per la loro preparazione” |
| GB202201825D0 (en) | 2022-02-11 | 2022-03-30 | Genome Res Ltd | Methods of treatment |
| IT202200007988A1 (it) | 2022-04-22 | 2023-10-22 | Fondazione St Italiano Tecnologia | Derivati del 4-cromone come inibitori della polimerasi ¿ come agenti antitumorali e metodo per la loro preparazione |
| JP7546104B2 (ja) * | 2022-05-27 | 2024-09-05 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬 |
| WO2023229032A1 (ja) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| CN116199569A (zh) * | 2023-02-22 | 2023-06-02 | 浙江科聚生物医药有限公司 | 一种抗肿瘤药物林扎戈利关键酚类中间体的制备方法 |
| WO2025027560A1 (en) | 2023-08-01 | 2025-02-06 | Fondazione Istituto Italiano Di Tecnologia | New rhoj/cdc42 inhibitors developed for the treatment of cancer, benign tumors, retinal disorders, vascular disorders, and cardiomyopathies |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| WO2025109026A1 (en) | 2023-11-21 | 2025-05-30 | Intervet International B.V. | Process for the preparation of 4-fluoro-3-methoxyaniline |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| JP2006528661A (ja) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用 |
| US20050148643A1 (en) | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
| AU2004312193B2 (en) | 2004-01-05 | 2008-09-25 | Astrazeneca Ab | Thiophene derivatives as CHK 1 inihibitors |
| CN101010316A (zh) | 2004-07-02 | 2007-08-01 | 艾科斯有限公司 | 用于抑制chk1的化合物 |
| BRPI0514466A (pt) | 2004-08-19 | 2008-06-10 | Icos Corp | composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante |
| EP2330105A1 (en) | 2005-03-29 | 2011-06-08 | ICOS Corporation | Heteroaryl urea derivatives useful for inhibiting CHK1 |
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| JO3145B1 (ar) | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| KR101884960B1 (ko) * | 2010-11-16 | 2018-08-30 | 어레이 바이오파마 인크. | 체크포인트 키나제 1 억제제 및 wee 1 키나제 억제제의 조합 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
-
2016
- 2016-02-04 SI SI201631439T patent/SI3411036T1/sl unknown
- 2016-02-04 CN CN201680066535.6A patent/CN108601781B/zh active Active
- 2016-02-04 KR KR1020187024712A patent/KR102159442B1/ko active Active
- 2016-02-04 PL PL16888753T patent/PL3411036T3/pl unknown
- 2016-02-04 PT PT168887537T patent/PT3411036T/pt unknown
- 2016-02-04 CA CA3013514A patent/CA3013514C/en active Active
- 2016-02-04 HU HUE16888753A patent/HUE057976T2/hu unknown
- 2016-02-04 HR HRP20220351TT patent/HRP20220351T1/hr unknown
- 2016-02-04 DK DK16888753.7T patent/DK3411036T3/da active
- 2016-02-04 JP JP2018541333A patent/JP6794609B2/ja active Active
- 2016-02-04 ES ES16888753T patent/ES2906785T3/es active Active
- 2016-02-04 WO PCT/CN2016/073454 patent/WO2017132928A1/en not_active Ceased
- 2016-02-04 US US16/074,195 patent/US11116767B2/en active Active
- 2016-02-04 EP EP16888753.7A patent/EP3411036B1/en active Active
- 2016-02-04 AU AU2016391377A patent/AU2016391377B2/en active Active
-
2017
- 2017-01-09 TW TW106100635A patent/TWI623533B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE057976T2 (hu) | 2022-06-28 |
| EP3411036B1 (en) | 2021-12-29 |
| HRP20220351T1 (hr) | 2022-05-13 |
| EP3411036A4 (en) | 2019-06-26 |
| EP3411036A1 (en) | 2018-12-12 |
| CN108601781B (zh) | 2019-11-22 |
| TW201728579A (zh) | 2017-08-16 |
| KR102159442B1 (ko) | 2020-09-24 |
| US20210137918A1 (en) | 2021-05-13 |
| JP2019509990A (ja) | 2019-04-11 |
| AU2016391377B2 (en) | 2019-07-18 |
| CA3013514C (en) | 2021-11-23 |
| HK1257988A1 (zh) | 2019-11-01 |
| ES2906785T3 (es) | 2022-04-20 |
| AU2016391377A1 (en) | 2018-08-16 |
| JP6794609B2 (ja) | 2020-12-02 |
| DK3411036T3 (da) | 2022-01-17 |
| TWI623533B (zh) | 2018-05-11 |
| CA3013514A1 (en) | 2017-08-10 |
| PT3411036T (pt) | 2022-02-21 |
| SI3411036T1 (sl) | 2022-03-31 |
| WO2017132928A1 (en) | 2017-08-10 |
| CN108601781A (zh) | 2018-09-28 |
| US11116767B2 (en) | 2021-09-14 |
| KR20180105700A (ko) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3411036T1 (sl) | 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba | |
| ZA201800671B (en) | Pyrazole pyrimidine derivative and uses thereof | |
| ZA201707423B (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| DK3359541T3 (da) | N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse | |
| DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
| EP3171874A4 (en) | Imidazolyl kinase inhibitors and uses thereof | |
| IL247426A0 (en) | Pyrazole amide derivatives, preparations containing them and their uses | |
| DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
| SG11202103142TA (en) | Heterocyclic kinase inhibitors and uses thereof | |
| IL272055A (en) | 8,1-naphthyridinone compounds and their uses | |
| EP3256450A4 (en) | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| PT3577094T (pt) | Mistura contendo 3,4-dimetilpirazol e a sua utilização | |
| ZA202004311B (en) | Pyrazole amide compound and application thereof, and fungicide | |
| DK3719021T3 (da) | Inhibitorer af adapterassocieret kinase 1, sammensætninger omfattende disse og fremgangsmåder til anvendelse deraf | |
| IL254152A0 (en) | Pyrimidine derivatives as kinase inhibitors and their medicinal uses | |
| EP3327021A4 (en) | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | |
| EP3476848A4 (en) | BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR | |
| IL252986B (en) | 5,3-diaminopyrazole kinase inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| IL257735B (en) | 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis | |
| HK40026701A (en) | Kinase inhibitors and uses thereof | |
| HK40036603A (en) | Heterocyclic compounds and uses thereof | |
| EP3634406C0 (en) | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF |